Compare Gilead Sciences, Inc. (GILD) vs iShares MSCI China ETF (MCHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs iShares MSCI China ETF — how do they compare? Gilead Sciences, Inc. trades at $135.28 (market cap $168.35B), while iShares MSCI China ETF trades at $55.86. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while iShares MSCI China ETF pays none, and Gilead Sciences, Inc. is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| GILD | MCHI | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $155.80 | $66.99 |
52-Week Low | $110.56 | $50.48 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MCHI trades at $56.57, up 1.19% with strong technical momentum showing bullish moving averages and institutional buying interest. The ETF benefits from China's export strength and AI-driven manufacturing growth, though key financial ratios remain undisclosed. Recent news highlights China's 23% July export surge and $295 billion AI infrastructure plan, creating positive sentiment around Chinese equities.
Outlook remains cautiously optimistic with technical indicators signaling strength but RSI levels suggesting potential overbought conditions. Key risks include US-China trade tensions and regulatory uncertainties, while institutional flows and China's tech investment push provide upside catalysts for continued momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →
